Heartflow, Inc. (HTFL)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $4.2M
- Nov 17 · Routine
- Form 4 sales
- 29
- On record
- Form 144 notices
- 0
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleRoutineAug 21 2026
Sold 27,230 shares at $50.00 ($1.4M)
Farquhar John C.M., Chief Executive Officer
10b5-1 planSold 7% of holdings ($19.4M position)360,814 shares left1.2x usual sizeFiling
- 2 Form 4 saleRoutineSep 3 +13 days
Sold 33,416 shares at $49.85 ($1.7M)
Verghese Vikram, Chief Financial Officer
10b5-1 planSold 13.1% of holdings ($12.7M position)221,143 shares leftFirst sale on recordFiling
- 3 Form 4 saleRoutineSep 8 +5 days
Sold 6,640 shares at $50.03 ($332k)
Verghese Vikram, Chief Financial Officer
10b5-1 planSold 3% of holdings ($11.1M position)214,503 shares leftFiling
- 4 Form 4 saleRoutineSep 11 +3 days
Sold 38,900 shares at $46.78 ($1.8M)
Farquhar John C.M., Chief Executive Officer
10b5-1 planSold 10.8% of holdings ($16.9M position)321,914 shares left1.7x usual sizeFiling
- 5 Form 4 saleRoutineSep 15 +4 days
Sold 34,975 shares at $50.08 ($1.8M)
Verghese Vikram, Chief Financial Officer
10b5-1 planSold 16.3% of holdings ($10.7M position)179,528 shares leftFiling
- 6 Form 4 saleRoutineSep 18 +3 days
Sold 24,345 shares at $50.55 ($1.2M)
Verghese Vikram, Chief Financial Officer
10b5-1 planSold 13.6% of holdings ($9.1M position)155,183 shares left0.7x usual sizeFiling
- 7 Form 4 saleRoutineSep 18 same day
Sold 19,682 shares at $50.15 ($987k)
Rogers Campbell, Chief Medical Officer
10b5-1 planSold 19.8% of holdings ($5M position)79,956 shares left0.5x usual sizeFiling
- 8 Form 4 saleRoutineNov 17 +60 days
Sold 111,412 shares at $37.86 ($4.2M)
Rogers Campbell, Chief Medical Officer
10b5-1 planSold 94.5% of holdings ($4.5M position)6,503 shares leftFiling
Every transaction
Loading transactions…
Sales, notices and lockups (29)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Nov 17, 2026 | Rogers Campbell | Chief Medical Officer | Form 4 sale | 111,412 | $4.2M | 94.5% | Routine | SEC |
| Sep 18, 2026 | Rogers Campbell | Chief Medical Officer | Form 4 sale | 19,682 | $987k | 19.8% | Routine | SEC |
| Sep 18, 2026 | Verghese Vikram | Chief Financial Officer | Form 4 sale | 24,345 | $1.2M | 13.6% | Routine | SEC |
| Sep 15, 2026 | Verghese Vikram | Chief Financial Officer | Form 4 sale | 34,975 | $1.8M | 16.3% | Routine | SEC |
| Sep 11, 2026 | Farquhar John C.M. | Chief Executive Officer | Form 4 sale | 38,900 | $1.8M | 10.8% | Routine | SEC |
| Sep 8, 2026 | Verghese Vikram | Chief Financial Officer | Form 4 sale | 6,640 | $332k | 3.0% | Routine | SEC |
| Sep 3, 2026 | Verghese Vikram | Chief Financial Officer | Form 4 sale | 33,416 | $1.7M | 13.1% | Routine | SEC |
| Aug 21, 2026 | Farquhar John C.M. | Chief Executive Officer | Form 4 sale | 27,230 | $1.4M | 7.0% | Routine | SEC |
| Aug 18, 2026 | Farquhar John C.M. | Chief Executive Officer | Form 4 sale | 32,676 | $1.5M | 7.8% | Routine | SEC |
| Aug 17, 2026 | Rogers Campbell | Chief Medical Officer | Form 4 sale | 9,219 | $380k | 9.6% | Routine | SEC |
| Aug 14, 2026 | Farquhar John C.M. | Chief Executive Officer | Form 4 sale | 15,560 | $608k | 3.6% | Routine | SEC |
| Aug 10, 2026 | Farquhar John C.M. | Chief Executive Officer | Form 4 sale | 22,562 | $639k | 4.9% | Routine | SEC |
| Jul 15, 2026 | Rogers Campbell | Chief Medical Officer | Form 4 sale | 9,219 | $237k | 9.4% | Routine | SEC |
| Jul 10, 2026 | Farquhar John C.M. | Chief Executive Officer | Form 4 sale | 22,562 | $626k | 4.9% | Routine | SEC |
| Jun 24, 2026 | Farquhar John C.M. | Chief Executive Officer | Form 4 sale | 38,900 | $1.4M | 7.8% | Routine | SEC |
| Jun 10, 2026 | Farquhar John C.M. | Chief Executive Officer | Form 4 sale | 22,562 | $643k | 4.3% | Routine | SEC |
| May 18, 2026 | Rogers Campbell | Chief Medical Officer | Form 4 sale | 9,219 | $261k | 10.5% | Routine | SEC |
| May 11, 2026 | Farquhar John C.M. | Chief Executive Officer | Form 4 sale | 22,562 | $657k | 4.2% | Routine | SEC |
| Apr 30, 2026 | Bain Capital Life Sciences III General Partner, LLC | 10% owner | Form 4 sale | 2M | $58.9M | 19.1% | No plan | SEC |
| Apr 10, 2026 | Farquhar John C.M. | Chief Executive Officer | Form 4 sale | 22,562 | $603k | 3.9% | Routine | SEC |
| Apr 1, 2026 | Rogers Campbell | Chief Medical Officer | Form 4 sale | 64,533 | $1.6M | 44.3% | Routine | SEC |
| Mar 19, 2026 | Rogers Campbell | Chief Medical Officer | Form 4 sale | 64,533 | $1.7M | 45.1% | Routine | SEC |
| Mar 18, 2026 | Farquhar John C.M. | Chief Executive Officer | Form 4 sale | 9,725 | $243k | 1.7% | Routine | SEC |
| Mar 10, 2026 | Farquhar John C.M. | Chief Executive Officer | Form 4 sale | 12,837 | $291k | 2.2% | Routine | SEC |
| Mar 5, 2026 | Cullivan Julie A | Director | Form 4 sale | 9,122 | $228k | 25.1% | Routine | SEC |
| Feb 12, 2026 | Rogers Campbell | Chief Medical Officer | Form 4 sale | 65,153 | $1.6M | 46.1% | Routine | SEC |
| Feb 10, 2026 | Farquhar John C.M. | Chief Executive Officer | Form 4 sale | 22,562 | $620k | 3.7% | Routine | SEC |
| Feb 5, 2026 | Cullivan Julie A | Director | Form 4 sale | 8,000 | $219k | 18.0% | Routine | SEC |
| Feb 4, 2026 | Bain Capital Life Sciences Investors, LLC | 10% owner | Form 4 sale | 2M | $56.1M | 16.1% | No plan | SEC |